Phoenix, June 22, 2017 (GLOBE NEWSWIRE) -- / At the recent ExpoMed Show in Mexico City, BioNovelus (ONOV) Chairman and founder, Jean Ekobo, was proud to introduce the newest addition to the Company’s product line. Eco Claro™ is an innovative disinfectant and antiseptic that safely addresses the growing problem of nosocomial infections.
Eco Claro™ quickly eradicates many strains of bacteria, spores, and molds, some in as little as 30 seconds, and has a lasting effect on surfaces of up to 10 hours as a disinfectant based on an independent lab study. [Micro Quality Labs Inc., CA; Dr. H. Al-Tawela] The product is designed to work both as a disinfectant, meant to be used to disinfect hard surfaces and medical instruments, as well as an antiseptic used directly on patients to disinfect wounds and to control infections. To date, there have been no commercial sales of the product as the Company is still exploring the required regulatory compliance for commercial sale in Mexico.
“Eco Claro™ is one of these promising applications,” says Ekobo. “We were very gratified to see that interest in the product was so high at ExpoMed. We are working with regulatory agencies to see which applications require registrations. If exempt from registration in Mexico, it could be available on the Mexican market soon.
BioNovelus is working with the Mexican Trade Office in partnership with the Arizona Commerce Authority to bring Eco Claro™ first to the Mexican market. “They have an effective team of people helping us with market research, connections, and the like,” says Ekobo,
The Eco Claro™ Technology family of products consist of liquids and wipes. Eco Claro™ Disinfectant will be offered in a one-liter spray bottle, and in four-liter jugs, and twenty-liter drums, while Eco Claro™ Wipes will be offered in canisters, and in boxes of 25 individually-wrapped wipes.
About BioNovelus Inc. BioNovelus, Inc. (ONOV) is a bioscience company that honors the environment with an innovative, cost-effective and disruptive solution, bringing the best of science and nature, to food security (Crop Protection and Post-Harvest Sanitation) and health challenges.
About ExpoMed ExpoMed is a trade show in Mexico City that brings together leading companies and brands that specialize in innovation and technology for equipment, conditioning and re-engineering of public and private health institutions, organizations, and corporations. More information can be found at http://www.expomed.com.mx/index.php/en/.
Forward-Looking Statements This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for the fiscal year 2017 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.
Factors that could cause the Company’s results to differ materially from forward-looking statements regarding the efficacy of Eco Claro™ include timing of applications of Eco Claro™, the strength of contamination, and other environmental conditions resulting in re-infection, the impact of large-scale commercialization on the results as compared to the results in the lab, the dosage applied, the ongoing exposure to bacteria, spores and molds and related extent of reapplication, the existence of other chemicals, temperature or humidity at the time of application, variation in demand and acceptance of the Company's products and services, ability to manufacture and obtain the Eco Claro™ product and import it to Mexico, the ability to obtain distributors of the product, the regulatory environment and whether the Company can comply with the regulations required for distribution and sale of the product, general business and economic conditions beyond the Company's control, the ability to raise capital necessary to market and sell the product, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements because of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
— 30 —
Media contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. +1 602-888-3424 Info@BioNovelus.com
